Unique ID issued by UMIN | UMIN000003897 |
---|---|
Receipt number | R000004647 |
Scientific Title | Evaluation of efficacy and safety of fluoroquinolone in patients with nongonococcal urethritis |
Date of disclosure of the study information | 2010/07/31 |
Last modified on | 2010/07/03 01:30:38 |
Evaluation of efficacy and safety of fluoroquinolone in patients with nongonococcal urethritis
Evaluation of efficacy and safety of fluoroquinolone in patients with nongonococcal urethritis
Evaluation of efficacy and safety of fluoroquinolone in patients with nongonococcal urethritis
Evaluation of efficacy and safety of fluoroquinolone in patients with nongonococcal urethritis
Japan |
nongonococcal urethritis (Chlamydia trachomatis urethritis, Mycoplasma genitalium urethritis)
Infectious disease | Urology |
Others
NO
We evaluate efficacy and safety of levofloxacin 500mg administered orally once daily in patients with nongonococcal urethritis
Safety,Efficacy
bacteriological efficacy two weeks after the end of treatment by levoflixacin
clinical efficacy two weeks after the end of treatment by levofloxacin
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Medicine |
levofloxacin 500mg once daily p.o. 7days
20 | years-old | <= |
Not applicable |
Male
1)age: more than 20 years old
2)sex: male
3)outpatient or hospitalization: both are included
4)patient with suspicious symptoms of nongonococcal urethritis
5)patient detected C. trachomatis or M. genitalium by bacteriological examination
1)patient detected N.gonorrhoeae by microscopic examination or bacteriological examination etc.
2)patient who has been administered other antibiotics and his symptom has been improved before starting administration of the study drug
3)patient administered fluoroquinolone within a week before starting administration of the study drug
4)patient with severe infection desease, who cannot be expected efficacy of oral administration therapy
5)patient with severe underlying disease or complications, who cannot be evaluated efficacy and safety of the study drug
6)patient with a history of fluoroquinolone allergies
7)patient with severe cardiac or hepatic dysfunction
8)patient with moderate renal dysfunction (Criteria: Serum Creatinine >= 2mg/dL)
9)patient with convulsive disorders like epilepsy or with a history of these deseases
10)patient disqualified as target by doctor
20
1st name | |
Middle name | |
Last name | Shoichi Onodera |
Jikei University School of Medicine
Department of Infectious Diseases and Infection Control
3-25-8 Nishi-Shimbashi Minato-ku Tokyo Japan
1st name | |
Middle name | |
Last name |
Jikei University School of Medicine
Department of Infectious Diseases and Infection Control
3-25-8 Nishi-Shimbashi Minato-ku Tokyo Japan
Department of Infectious Diseases and Infection Control, Jikei University School of Medicine
Department of Infectious Diseases and Infection Control, Jikei University School of Medicine
Self funding
NO
東京慈恵会医科大学附属病院(東京都)
2010 | Year | 07 | Month | 31 | Day |
Unpublished
Preinitiation
2010 | Year | 06 | Month | 30 | Day |
2010 | Year | 07 | Month | 01 | Day |
2010 | Year | 07 | Month | 09 | Day |
2010 | Year | 07 | Month | 03 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000004647
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |